Comparative pharmacokinetics of propranolol and atenolol in primary hyperlipidemia

Polish Journal of Pharmacology

Volumn 55, Issue 1, 2003, Pages 81-89

  Telatyńska, Bogumiła ^a   Wójcicki, Jerzy ^a   Droździk, Marek ^a   Gawrońska Szklarz, Barbara ^a   Sulzyc Bielicka, Violetta ^a   Sterna, Rozalia ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Atenolol; Hyperlipidemia; Pharmacokinetics; Propranolol

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; LIPID; PROPRANOLOL; TRIACYLGLYCEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HYDROPHILICITY; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPOPHILICITY; MALE; SINGLE DRUG DOSE; TIME;

ADULT; AREA UNDER CURVE; ATENOLOL; CROSS-OVER STUDIES; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PROPRANOLOL; STATISTICS, NONPARAMETRIC;

EID: 12444309372     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Adamska-Dyniewska H.: β-adrenolytics - an update. Probl. Ter. Monit., 1998, 9, 143-149.
2. Braillon A., Capron J.P., Herve M.A., Degott C., Quenum C.: Liver in obesity. Gut, 1985, 26, 133-139.
3. Candella P.J., Grouthamel W.G., Bierkamper G.G., Westfoll D.P.: Alteration of drug pharmacodynamics by hyperlipidemia. Arch. Int. Pharmacodyn. Thér. 1975, 218, 299-311.
4. Cheymol G., Poirier J.M., Carrupt P.A., Testa B., Weissenburger J., Levron J.C., Snoeck E.: Pharmacokinetics of β-adrenoceptor blockers in obese and normal volunteers. Brit. J. Clin. Pharmacol., 1997, 43, 563-570.
5. Droździk M., Gawrońska-Szklarz B., Wójcicki J.: The pharmacokinetics of phenytoin in rabbits with hyperlipidemia induced by high-fat diet. Acta Pol. Pharm., 1994, 51, 517-520.
6. Duchateau G.S., Zuidema J., Merkus F.W.: Bioavailability of propranolol after oral, sublingual and intranasal administration. Pharmacokin. Res., 1986, 3, 108-111.
7. Dutkiewicz; G., Wójcicki J., Gawrońska-Szklarz B.: Pharmacokinetics of phenytoin in hyperlipidemia. Eur. J. Pharmacol. Sci., 1996, 4, 33-37.
8. Fitzgerald J.D., Ruffin R., Smedstad K.G., Roberts R., McAinsh J.: Studies of the pharmacokinetics and pharmacodynamics of atenolol in man. Eur. J. Clin. Pharmacol., 1978, 13, 81-89.
9. Frishman W.: Clinical pharmacology of the new beta-adrenergic blocking drugs. Pharmacodynamic and pharmacokinetic properties. Amer. Heart J., 1979, 97, 663-669.
10. Galletti F., Fasano M.L., Ferrara L.A.: Obesity and beta-blockers: influence of body fat on their kinetics and cardiovascular effects. J. Clin. Pharmacol., 1989, 29, 212-216.
11. Gawrońska-Szklarz B., Droździk M., Juźwiak S., Musial H.D., Wójcicki J., Zakrzewski J.: Efeito da hiperlipidemia experimental na farmacocinetica da procainamida e acecainida. Rev. Farm. Bioquim. Univ. S. Paulo, 1994, 30, 13-16.
12. Gawrońska-Szklarz B., Droździk M., Wójcicki J., Zakrzewski J.: Effect of experimental hyperlipidemia on the pharmacokinetics of digoxin. Acta Pol. Pharm., 1994, 51, 271-275.
13. Gawrońska-Szklarz B., Kalinowski W., Wójcicki J.: Effect of hypertriglyceridemia on the pharmacokinetics of tetracyclines (Polish). Pol. Tyg. Lek., 1984, 39, 295-298.
14. Gengo F.M., Huntoon L., Wiliam B., McHugh C.: Lipid-soluble and water-soluble β-blockers. Arch. Intern. Med., 1987, 47, 39-43.
15. Hermansson J., von Bahr C.: Simultaneous determination of d- and l-propranolol in human plasma by high performance liquid chromatography. J. Chromatogr. Biomed. Appl., 1980, 221, 109-117.
16. Kutrzeba J., Gawrońska-Szklarz B., Górnik W., Wójcicki J.: Pharmacokinetics of procainamide in hyperlipidemia (Polish). Pol. Tyg. Lek., 1993, 48, 50-52.
17. Masiakowski J., Wegner B., Ignys B.: Influence of hyperlipidemia on pharmacokinetic parameters of digoxin in rabbits. Acta Pol. Pharm., 1988, 45, 445-448.
18. Ochs H.R., Greenblatt D.J., Arendt R.M., Schaffer-Korting C., Mutschler E.: Single-dose kinetics of oral propranolol, metoprolol, atenolol, and sotalol: relation to lipophilicity. Arzneim.-Forsch.-Drug Res., 1985, 35, 1580-1582.
19. 1-acid glycoprotein. N. Engl. J. Med., 1978, 299, 1435-1439.
20. Poirier J.M., Le Jeune C., Cheymol G., Cohen A., Barre J.: Comparison of propranolol and sotalol pharmacokinetics in obese subjects. J. Pharm. Pharmacol., 1990, 42, 344-348.
21. Sager G., Nilsen O.G., Jacobsen S.: Variable binding of propranolol in human serum. Biochem. Pharmacol., 1978, 28, 905-911.
22. Sirtori C.R., Johnson B., Vaccarino V., Montanari G., Cremonicini M., Gianfranceschi G., Sirtori M., Dujovne C.A.: Lipid effect of celiprolol a new cardioselective beta-blocker versus propranolol. Clin. Pharmacol. Ther., 1989, 45, 617-625.
23. Sulzyc-Bielicka V, Droździk M., Gawrońska-Szklarz B., Sterna R.: Effect of hydroxylation phenotype on the course of concentration of propranolol in the blood of humans with hyperlipidemia (Polish). Pol. Merk. Lek. 1999, 7, 256-258.
24. Ueno T., Sugawara H., Sujaku K., Hashimoto O., Tsuji R., Tamaki S.: Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J. Hepatol., 1997, 27, 103-107.
25. Wang T.D, Wu C.C., Chen W.J., Lee C.M., Chen M.F., Liau C.S., Sung F.C., Lee Y.T.: Dyslipidemias have a detrimental effect on left ventricular systolic function in patients with a first acute myocardial infarction. Amer. J. Cardiol., 1998, 81, 531-537.
26. Wójcicki J., Gawrońska-Szklarz B., Droździk M.: Effect of experimental hyperlipidemia on the pharmacokinetics of lidocaine. Pharmacol. Commun., 1996, 269, 20-30.
27. Wójcicki J., Kalinowski W., Gawrońska-Szklarz B.: Comparative pharmacokinetics of doxycycline and oxytetracycline in patients with hyperlipidemia. Arzneim.-Forsch.-Drug Res., 1985, 35, 911-993.
28. Wójcicki J., Sterna R., Sulzyc-Bielicka V., Gawrońska-Szklarz B., Droździk M., Musial H.D.: Effects of hypolipemic therapy on the pharmacokinetics of propranolol. Curr. Ther. Res., 1999, 60, 20-30.
29. Wójcicki J., Sulzyc-Bielicka V., Kutrzeba J., Gawrońska-Szklarz B., Droździk M., Sterna R.: Studies on the pharmacokinetics and pharmacodynamics of propranolol in hyperlipidemia. J. Clin. Pharmacol., 1999, 39, 826-833.
30. Wójcicki J., Wojciechowski G., Wójcicki M., Kostyrka R., Sterna R., Gawrońska-Szklarz B., Pawlik A., Droździk M., Kozłowski K.: Pharmacokinetics of propranolol and atenolol in patients after partial gastric resection: a comparative study. Eur. J. Clin. Pharmacol., 2000, 56, 75-79.